# Boehringer Ingelheim

Source: https://onco.cc/companies/boehringer-ingelheim/  
OnCo record `boehringer-ingelheim` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Private German pharma whose zongertinib became the first oral HER2 inhibitor for lung cancer.

## Summary

Boehringer Ingelheim, a private German pharmaceutical company based in Ingelheim, is the maker of zongertinib, sold as Hernexeos, which became the first oral HER2 inhibitor for lung cancer. Its oncology pipeline also includes brigimadlin, an MDM2 inhibitor, obrixtamig, a DLL3 by CD3 T-cell engager, and pan-KRAS inhibitor programmes, alongside the older kinase inhibitors afatinib and nintedanib. OnCo links it to non-small-cell lung cancer and mesothelioma, to MDM2 as a target, and to NBE-Therapeutics. Whether a private company can carry several first-in-class oncology programmes through phase 3 without a partner is the open question. Zongertinib has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Ingelheim
- Type: pharma
- Website: https://www.boehringer-ingelheim.com

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Boehringer_Ingelheim
- Official website: https://www.boehringer-ingelheim.com

## Connected records

- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Afatinib](https://onco.cc/drugs/afatinib/), [Brigimadlin](https://onco.cc/drugs/brigimadlin/), [Nintedanib](https://onco.cc/drugs/nintedanib/), [Obrixtamig](https://onco.cc/drugs/obrixtamig/), [Tasonermin](https://onco.cc/drugs/tasonermin/), [Zongertinib](https://onco.cc/drugs/zongertinib/)
- companies: [NBE-Therapeutics](https://onco.cc/companies/nbe-therapeutics/)
- trials: [A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine](https://onco.cc/trials/nct06619509/), [Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab](https://onco.cc/trials/nct07486817/), [Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People Wit](https://onco.cc/trials/nct06324357/), [Beamion LUNG-1](https://onco.cc/trials/beamion-lung-1/), [Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment](https://onco.cc/trials/nct06151574/), [Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati](https://onco.cc/trials/nct07195695/), [Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations](https://onco.cc/trials/nct06581432/), [DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment](https://onco.cc/trials/nct07472517/), [DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers](https://onco.cc/trials/nct07707895/), [DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy](https://onco.cc/trials/nct07544654/), [DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers](https://onco.cc/trials/nct05882058/), [LUME-Lung 1](https://onco.cc/trials/lume-lung-1/), [LUME-Meso](https://onco.cc/trials/lume-meso/), [LUX-Lung 3](https://onco.cc/trials/lux-lung-3/), [TAPUR (Targeted Agent and Profiling Utilization Registry)](https://onco.cc/trials/tapur/)
- cancers: [HER2-mutant non-small-cell lung cancer](https://onco.cc/cancers/her2-mutant-nsclc/), [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [MDM2](https://onco.cc/targets/mdm2/)

---
JSON: https://onco.cc/api/v1/entities/boehringer-ingelheim.json